NeuroDerm Ltd. (NASDAQ:NDRM) – Equities research analysts at Oppenheimer Holdings cut their Q3 2017 earnings estimates for shares of NeuroDerm in a note issued to investors on Wednesday. Oppenheimer Holdings analyst J. Olson now expects that the biotechnology company will earn ($0.58) per share for the quarter, down from their previous forecast of ($0.51). Oppenheimer Holdings currently has a “Outperform” rating and a $42.00 target price on the stock. Oppenheimer Holdings also issued estimates for NeuroDerm’s Q4 2017 earnings at ($0.62) EPS, FY2017 earnings at ($2.26) EPS, FY2018 earnings at ($2.29) EPS, FY2019 earnings at $4.39 EPS, FY2020 earnings at $6.69 EPS and FY2021 earnings at $9.60 EPS.

NDRM has been the topic of several other reports. CIBC upgraded shares of NeuroDerm from a “market perform” rating to an “outperform” rating and set a $42.00 price objective on the stock in a research report on Wednesday, June 14th. Roth Capital cut shares of NeuroDerm from a “buy” rating to a “neutral” rating and lifted their price objective for the stock from $33.00 to $39.00 in a research report on Wednesday, August 2nd. Deutsche Bank AG began coverage on shares of NeuroDerm in a research report on Friday, July 21st. They set a “buy” rating and a $47.00 price objective on the stock. Zacks Investment Research cut shares of NeuroDerm from a “hold” rating to a “sell” rating in a research report on Saturday, July 15th. Finally, BidaskClub upgraded shares of NeuroDerm from a “sell” rating to a “hold” rating in a research report on Tuesday, July 25th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $44.13.

ILLEGAL ACTIVITY WARNING: “Equities Analysts Offer Predictions for NeuroDerm Ltd.’s Q3 2017 Earnings (NDRM)” was originally published by American Banking News and is owned by of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.americanbankingnews.com/2017/08/18/equities-analysts-offer-predictions-for-neuroderm-ltd-s-q3-2017-earnings-ndrm.html.

NeuroDerm (NASDAQ NDRM) opened at 38.55 on Friday. The stock’s market cap is $1.02 billion. The firm’s 50 day moving average price is $34.70 and its 200-day moving average price is $27.95. NeuroDerm has a 52 week low of $15.20 and a 52 week high of $38.85.

Several institutional investors have recently bought and sold shares of the stock. Van ECK Associates Corp boosted its position in NeuroDerm by 11.0% in the second quarter. Van ECK Associates Corp now owns 4,723 shares of the biotechnology company’s stock valued at $141,000 after buying an additional 468 shares in the last quarter. Vanguard Group Inc. bought a new position in NeuroDerm during the second quarter valued at approximately $210,000. ETF Managers Group LLC bought a new position in NeuroDerm during the second quarter valued at approximately $210,000. Oppenheimer & Co. Inc. bought a new position in NeuroDerm during the first quarter valued at approximately $223,000. Finally, Nationwide Fund Advisors bought a new position in NeuroDerm during the first quarter valued at approximately $226,000. Institutional investors and hedge funds own 53.22% of the company’s stock.

About NeuroDerm

NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages.

Earnings History and Estimates for NeuroDerm (NASDAQ:NDRM)

Receive News & Ratings for NeuroDerm Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroDerm Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.